The GORE® TIGRIS® Vascular Stent delivers the ideal combination for high-flexion performance in the proximal popliteal.

  • Conformability that retains the natural shape of the vessel, allowing axial compression while resisting stent elongation
  • Flexibility that enables movement in high-flexion anatomy, allowing natural vessel movement
  • Long-term fracture resistance with zero reported stent frame fractures at
    36 months1
93% primary patency at 12 months
95% freedom from TLR at 12 months
100% secondary patency at 12 months


GORE® TIGRIS® Vascular Stent: Advanced technology engineered for lasting performance.

Giving you the confidence that you are delivering the most durable treatment options to your patients.

  • Clinically established helically-wound nitinol frame, leverages the stent technology of the GORE® VIABAHN® Endoprosthesis, provides luminal radial strength
  • Fluoropolymer interconnecting structure enables performance in high-flexion anatomies
  • CBAS Heparin Surface, also featured in the GORE® PROPATEN® Vascular Graft, is the proven, lasting heparin technology designed to resist thrombus formation*

High-flexion conformability: Optimal combination of straightening force and elongation, allowing the artery to bend and move naturally.3

chart showing incidence of fracture rate

Long-term fracture resistance: Zero reported stent frame fractures at 12, 24, and 36 months.4

less than 0.1% average elongation

Accuracy with minimal elongation: Average elongation < 0.1% in a U.S. Clinical Study.5

precision delivery

On target, every time: Single-handed, precise delivery — 100% of stents deployed within the nominal length.1

impact of CBAS Heparin surface

Proven lasting thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity.*

* CBAS Heparin Surface. W. L. Gore & Associates web site. Accessed July 30, 2018.

** Tested as IDEV® SUPERA® Stent

ABBOTT® and SUPERA® are trademarks of Abbott Laboratories.
BD® and LIFESTENT® are trademarks of Becton, Dickinson, and Company.
COOK®, ZILVER®, and PTX® are trademarks of Cook Medical Inc.

  1. U.S. Food and Drug Administration. Center for Devices and Radiological Health. FDA Summary of Safety and Effectiveness Data. P160004. Published July 27, 2016. Accessed August 10, 2016.
  2. Werner M. The Tigris dual component stent (from Gore): advantages and 1-year results in treating SFA-pop occlusive lesions: from the Austrian Registry. Presented at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium); November 13-17, 2018; New York, NY.
  3. Hoopingarner E. TIGRIS / Viabahn Stent Competitor Testing. Part 2. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2014. [Work plan]. WP106734.
  4. W. L. Gore & Associates, Inc. Evaluation of the GORE® TIGRIS® Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries. [Final Post-Approval Study Report-Executive
    Summary]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2017. MD165299.
  5. Laird JR, Zeller T, Loewe C, et al. Novel nitinol stent for lesions up to 24 cm in the superficial femoral artery and proximal popliteal arteries: 24-month results from the TIGRIS Randomized Trial. Journal of Endovascular Therapy
  6. Supera® Peripheral Stent System [Instructions for Use]. Santa Clara, CA: Abbott Vascular; 2016. EL2100430.
  7. Biran R. Thromboresistance Evaluation of the GORE® TIGRIS Vascular Stent and Commercial Competitor Stents in an In Vitro Blood Contact Model. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2012. [Work plan]. WP 103833.


GORE TIGRIS Vascular Stent